SCHEMBL3565214

SCHEMBL3565214

COc1ccccc1-c1cn(S(=O)(=O)c2ccc(C)cc2)c2ncc(-c3cc(F)c(NC(=O)C(F)(F)F)c(C(=O)N(C)C)c3)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 2/20 0.40
PTPN11 Q06124 1/20 0.39
ABL1 P00519 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.35
MAPT P10636 2/20 0.35
TSHR P16473 2/20 0.35
PIM1 P11309 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
SLC1A3 P43003 1/20 0.33
SLC1A2 P43004 1/20 0.33
SLC1A1 P43005 1/20 0.33
MEN1 O00255 2/20 0.33
HTT P42858 2/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
LMNA P02545 1/20 0.32
MAPK1 P28482 1/20 0.32
HTR6 P50406 2/20 0.31
GPBAR1 Q8TDU6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13816796 0.91 MAP4K1 (0.40) MAP4K1PTPN11ABL1SMN1; SMN2MAPT
SCHEMBL3562857 0.90 MAP4K1 (0.39) MAP4K1PTPN11ABL1SMN1; SMN2MAPT
SCHEMBL3563287 0.88 PTPN11 (0.43) MAP4K1PTPN11ABL1SMN1; SMN2MAPT
SCHEMBL13342389 0.87 USP2 (0.37) MAP4K1PTPN11ABL1SMN1; SMN2TSHR
SCHEMBL3566926 0.87 MAP4K1 (0.45) MAP4K1PTPN11ABL1SMN1; SMN2MAPT
SCHEMBL3564430 0.86 MAP4K1 (0.39) MAP4K1PTPN11ABL1SMN1; SMN2MAPT
SCHEMBL3566923 0.86 MAP4K1 (0.42) MAP4K1PTPN11ABL1SMN1; SMN2MAPT
SCHEMBL3562904 0.84 PIK3CA (0.39) MAP4K1PTPN11ABL1ALDH1A1LMNA
SCHEMBL3573801 0.84 PTPN11 (0.40) MAP4K1PTPN11ABL1SMN1; SMN2MAPT
SCHEMBL1516677 0.83 PTPN11 (0.43) MAP4K1PTPN11ABL1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS SGX PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS SGX PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
WO-2008124849-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS MAP4K2, PDXK, MAP4K1 MAP4K1 3/4885PTPN11 1303/4885ABL1 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.